The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis

Evidence about COVID-19 on cardiac injury is inconsistent. We aimed to summarize available data on severity differences in acute cardiac injury and acute cardiac injury with mortality during the COVID-19 outbreak. We performed a systematic literature search across Pubmed, Embase and pre-print from D...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Progress in cardiovascular diseases Ročník 63; číslo 4; s. 518 - 524
Hlavní autoři: Li, Jing-Wei, Han, Tian-Wen, Woodward, Mark, Anderson, Craig S., Zhou, Hao, Chen, Yun-Dai, Neal, Bruce
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Elsevier Inc 01.07.2020
Published by Elsevier Inc
Témata:
Betacoronavirus
Cardiac injury
Coronavirus
Coronavirus Infections - complications
COVID-19
Heart Diseases - epidemiology
Heart Diseases - virology
Humans
Mortality
Pandemics
Pneumonia, Viral - complications
Review
SARS-CoV-2
RR
Cardiac injury
CI
Mortality
SARS-CoV
CK-MB
hsTnI
SMD
WMD
COVID-19
ACE2
NT-proBNP
Coronavirus
ISSN:0033-0620, 1873-1740, 1532-8643, 1873-1740
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Evidence about COVID-19 on cardiac injury is inconsistent. We aimed to summarize available data on severity differences in acute cardiac injury and acute cardiac injury with mortality during the COVID-19 outbreak. We performed a systematic literature search across Pubmed, Embase and pre-print from December 1, 2019 to March 27, 2020, to identify all observational studies that reported cardiac specific biomarkers (troponin, creatine kinase–MB fraction, myoglobin, or NT-proBNP) during COVID-19 infection. We extracted data on patient demographics, infection severity, comorbidity history, and biomarkers during COVID-19 infection. Where possible, data were pooled for meta-analysis with standard (SMD) or weighted (WMD) mean difference and corresponding 95% confidence intervals (CI). We included 4189 confirmed COVID-19 infected patients from 28 studies. More severe COVID-19 infection is associated with higher mean troponin (SMD 0.53, 95% CI 0.30 to 0.75, p < 0.001), with a similar trend for creatine kinase–MB, myoglobin, and NT-proBNP. Acute cardiac injury was more frequent in those with severe, compared to milder, disease (risk ratio 5.99, 3.04 to 11.80; p < 0.001). Meta regression suggested that cardiac injury biomarker differences of severity are related to history of hypertension (p = 0.030). Also COVID19-related cardiac injury is associated with higher mortality (summary risk ratio 3.85, 2.13 to 6.96; p < 0.001). hsTnI and NT-proBNP levels increased during the course of hospitalization only in non-survivors. The severity of COVID-19 is associated with acute cardiac injury, and acute cardiac injury is associated with death. Cardiac injury biomarkers mainly increase in non-survivors. This highlights the need to effectively monitor heart health to prevent myocarditis in patients infected with COVID-19. [Display omitted]
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
These authors contributed equally to this work.
ISSN:0033-0620
1873-1740
1532-8643
1873-1740
DOI:10.1016/j.pcad.2020.04.008